Bispecific Antibodies Survey

We are embarking on a national project to help implement bispecific antibodies as a treatment for multiple myeloma accessed through clinical trials, named patient schemes or routine care if NICE approvals are positive. To do this we would like to understand the challenges you may face with these treatments both with your hospital but also for patients. We are keen to hear from all centres irrespective of your current experience with these agents and particularly those from level 1 and level 2 centres as well as the tertiary centres.

Your feedback will enable us to shape this national work and we would be grateful if you would complete this on-line survey to help us tailor the project to your needs. It should take no more than 10 minutes.

The survey will be open until March 14th.

To obtain more information about this work please contact Dr. Pinkie Chambers ([email protected])

Latest News

By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article
By BOPA on 11th April 2024

My Research Webinar – April 2024

Thursday 25th April 2024 1-2pm BST   Register for the Session HERE:   We would like to invite you to join our  ‘My Research’ sessions. These sessions are delivered…

Read article
By BOPA Committee on 10th April 2024

Independent UK Pharmacy Professional Leadership Advisory Board launched to strengthen collaboration

BOPA is proud to be part of the UK PPL Board and represent all Pharmacy Professionals and Cancer Pharmacy Professionals across the UK. For more information see the letter on…

Read article